KR101953460B1 - Method and apparatus for preparing inhibitable vaccine for prevention of stability bacterial disease including protected serum form of new streptococcus paraberis - Google Patents

Abstract

The present invention relates to the use of alpha-hemolytic streptococcus parauberis HFTC0045 Streptococcus parauberis (microorganism deposit number KCTC 18522P), HFTC0049 Streptococcus parauberis A microorganism deposit number KCTC18523P), J101 Streptococcus parauberis (microorganism deposit number KCTC18525P), a mixed inactivated vaccine for preventing Streptococcus infestation including a defensive serotype strain, and a method for immunizing fish using the same will be.

Description

FIELD OF THE INVENTION The present invention relates to a method and a method for producing an inactivated vaccine for the prevention of intense leg bacterial diseases including a protective serotype of a novel Streptococcus parabeuris strain. PARABERIS}

The present invention relates to an intense leg-specific vaccine comprising two serotypes of novel Streptococcus strains, and to a mixed inactivated vaccine for preventing bacterial disease in a resistant leg. In addition, the present invention relates to a novel Streptococcus strain inactivating vaccine for preventing bacterial disease in a fish comprising an antigen of a known strain.

Streptococcal strains that develop on the strength legs include Streptococcus iniae , Streptococcus parauberis , Lactococcus garvieae ( Lactococcus garvieae) is a major causative organism. It is a disease that occurs extensively from fry to spermatozoa when the breeding environment for aquaculture is poor or management is poor. The main clinical manifestations of Strength Legs affected by streptococcal disease are poor feeding, poor appetite, poor swimming, revenge, kidney hypertrophy, darkening of the body, prominence and opacity, clouding of gills, gum mucus secretion of gills and bones And isolate the bacteria from the kidneys and spleen, or make a smear sample and examine them, it is possible to more clearly grasp the symptoms of streptococcal disease. In case of disease, it is most preferred to rapidly isolate and eliminate pathogens, or to supply immunity enhancers with feeds to prevent the spread of diseases, but it is most preferable to use a vaccine to prevent the disease from occurring . Currently, major licenses for domestic fish vaccines are focused on bacterial disease vaccines based on Streptococcus iniae , Streptococcus parauberis , and Edward tarda , The target fish species are concentrated in flounder except one product. The other one is also a viral disease prevention vaccine targeting red sea bream, defense, and red sea bream, and there are no vaccines that can be applied to the strength legs on the currently approved vaccine products. Given the fact that there are no validated data and there are many problems that may arise in the future, it is possible to use only a vaccine that can only be used on the strength legs, rather than expanding the existing vaccine. Development is more desirable.

(1) Published Patent Application No. 10-2011-0111154 (October 10, 2011) (2) Published Patent Publication No. 10-2004-0110146 (December 31, 2004) (3) Patent Application No. 10-2016-0166928 (Patent Document A)

Strength bridge derived from Streptococcus para Ube less was Streptococcus para Ube-less (Streptococcus parauberis) it is serotype type 1 which results, found in domestic strength bridge fishing grounds subjected to epidemiological studies on (Streptococcus parauberis), Streptococcus para Ube-less (Streptococcus parauberis ) Serotype 1 1a and 1b / c. According to the results of self-epidemiological studies, 1a and 1b / c types are present in Korea, and in laboratory experiments, 1a type and 1b / In the case of the c type, cross protection was not established mutually, and finally, it was confirmed that the combination of the 1a type 2 and 1b / c type 1 vaccine showed high defense power. Based on the results of previous studies, Streptococcus parauberis ( Streptococcus parauberis ) was developed to develop a vaccine against Streptococcus spp . Two types of 1a and one type 1b / c were selected for each vaccine, and a test vaccine containing all the defensive serotypes was prepared. The results of the safety and efficacy tests in the laboratory were excellent. As a result of comparing the protective effect of vaccine with that of the vaccine, it was confirmed that it is more effective to protect two types of 1a-type strains which contain different antibody aggregation ability than that containing only one type 1a. It was decided to include two strains of S.parauberis 1a and one species of S.parauberis 1b / c.

Accordingly, it is an object of the present invention to provide a novel streptococcal inactivated vaccine containing other serotypes which are not cross-protected, using strains isolated from intact legs infected with bacterial diseases.

 It is still another object of the present invention to provide a method for producing a novel streptococcal inactivated vaccine.

In order to achieve the above object, the present invention relates to a novel α-hemolytic Streptococcus parauberis HFTC 0045, an α-hemolytic Streptococcus parauberis HFTC 0049, an α-hemolytic streptococcus parauberis Streptococcus parauberis ) J101 antigen.

To achieve these and other objects, the present invention provides an inactivated vaccine for the prevention of bacterial disease of fish comprising inactivated Streptococcus parauberis HFTC 0045, HFTC 0049, J101 antigen. The present invention provides a method for producing a vaccine containing the above bacteria.

In order to accomplish the above object, a method for immunizing a fish characterized by injecting a vaccine into the abdominal cavity of a fish is provided.

The vaccine according to the present invention is an intensive leg-specific vaccine containing the serotype (1a, 1b / c) of Streptococcus parauberis derived from the Streptococcus parahaemolyticus strain . It can be effectively and economically prevented, and thus can be usefully used in aquaculture industries.

2 is a photograph of a purely isolated colony of the strain of S. parauberis grown in BHIA (Difco, USA) medium supplemented with 1.5% NaCl and in a rabbit serum medium (BAP).
3 shows specific primer information having a size of 718 bp as a 23S rRNA target primer sequence of the strain Streptococcus parauberis .
4] = Streptococcus parauberis Streptococcus parauberis [ 0159 ] Specific primer information having a size of 213 bp for each serotype and a size of 303 bp for 1 b / c is shown.
5] PCR was performed using a thermal cycler (Bio-rad, USA), and electrophoresis was performed on 1.5% agarose gel (agarose gel) + EtBr (ethidium bromide) to confirm the end product of 718 bp, and the result is shown in the band.
6] PCR was performed using a thermal cycler (Bio-rad, USA), and the resulting product was subjected to electrophoresis using 1.5% Agarose gel + EtBr And the final product of 213 bp and 303 bp was confirmed by performing electrophoresis on the resulting product.
[Figure 7], [Figure 8] and [Figure 9]: Streptococcus parauberis strain HFTC 0045 and HFTC 0049 J101 isolated from the intact legs were infected with the strain of fish of the public fish, It shows external symptoms and autopsy findings of the dead organism. The photographs showing lesions of the intact legs infected with the strain are mainly internal symptoms such as ocular protrusion, periocular abscess and hemorrhage, external perineal hemorrhage, external symptoms such as abdominal distension, liver congestion and congestion.
[Figure 10], [Figure 11], [Figure 12] = Sequence through 16S rRNA sequence using universal primer of 16S rRNA Streptococcus parauberis HFTC 0045, HFTC As a result of analysis of J101 strain, analysis was commissioned to a professional sequencing company (Bionicsro, Macrogen. Korea), and it was confirmed that the strain had high homology with KCTC11537 strain. Finally, the strain was identified as Streptococcus parauberis .
[Fig. 13], [Fig. 14] and [Fig. 15] = Each test subject used a strength leg of 11 to 14 cm (17g to 40g). The histopathological examination of the kidney, liver and spleen of the vaccinated group revealed that mitomycin C (MMC) was generally observed. Overall, the ellipsoid hypertrophy was not observed . Histopathologic findings of the normal category were shown in terms of the remaining organs, except for the slightly elevated Ellipsoid in the spleen. This suggests that the level of systemic infection of the pathogen is low or does not reach the threshold value to induce the inflammatory reaction and normal tissues are observed in all the organs of the vaccine treatments.
[Fig. 16], [Fig. 17], [Fig. 18] and [Fig. 19] = Each test subject used an intact leg of 11 to 14 cm (17g to 40g). In contrast to the vaccination group, the experimental animals that did not receive the immunization of the vaccine but received only the vaccination showed that the mitomycin C (MMC) was increased more in the kidney than the normal ones, and the majority of melanin was observed in some areas It can be observed that the macrophage is more active than the normal one because it can observe the phagocytosis of the macrophage.
In the liver, there is also atrophy of fatty liver. Monocytes in the hepatocytes are observed to exhibit invasion and predation activity.
A large amount of mitomycin C (MMC) was observed in the spleen and the ceroid and hemosiderin pigment were found to be higher than the melanin granules. Macrophages in the ellipsoid were activated , And ellipsoid (Ellipsoid). In the spleen, hematopoietic activity was observed locally. In some local areas, macrophages were activated and the ellipsoid (Ellipsoid) was observed to increase, resulting in an increase in mitomycin C (MMC) Is continuously observed as a tendency to actively affect the host or the internal striking element.

The present invention relates to novel α-hemolytic Streptococcus parauberis 1a type HFTC 0045, HFTC 0049 strain, and novel α-hemolytic Streptococcus parauberis 1b / c type J101 antigen to provide. The strains were analyzed for 16S rRNA sequences using a universal primer of 16S rRNA, and analyzed for each vaccinia strain from published strains to a professional sequencing company (Bionicsro, Macrogen. Korea), and finally Streptococcus parauberis ) KCTC11537 strain, and the results of analysis of each base sequence are shown in the following figures and tables.

 The new strain according to the present invention is a strain derived from a preliminary field isolate of Gyeongsangbuk-do Fishing Technology Center and a preliminary field isolate of JeBee Seonji's preliminary isolate strain (strain derived from Pohang) through HFSC 0045, HFTC 0049 , J101 strain, and the origin and main information of the strain are shown in Table 1 below.

The present invention provides an inactivated vaccine using the strain. Inactivated vaccine for bacterial disease prevention through serotypic distinction provides an inactivated vaccine for bacterial disease prevention comprising an exacerbated inactivated Streptococcus parauberis antigen. Such inactivated vaccines may be prepared using methods well known in the art and may be prepared, for example, using inactivating agents known in the art. The inactivated vaccine according to the present invention can prevent bacterial diseases that are most commonly caused in fish by inhibiting streptococcal disease. The vaccine according to the present invention can be used after being dispensed in a volume of 50 ml / bottle, 100 ml / bottle, 250 ml / bottle, 500 ml / bottle, 1000 ml / bottle and the like. Such a vaccine may be used not only as a liquid but also as a desiccant agent by separately injecting and then freeze-drying. The dry preparations can be used by completely re-dissolving the dry substance with the stimulant added immediately before use. The mixed inactivated vaccine according to the present invention can be used in any age fish at risk of infection. The present invention includes a method for producing the vaccine. Hereinafter, the present invention will be described in more detail with reference to examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.

Example 1: Isolation and identification of novel Streptococcus strains

We identified S. parauberis as a pathogenic strain of Streptococcus pneumoniae causing massive mortality in the intensive culture industry and raised the need for S. parauberis vaccine to prevent streptococcal disease. In addition, strains were isolated from the intestinal organs (liver, heart, kidney, spleen) and eyeballs infected with Streptococcus pneumoniae from Uljin, Pohang, Jeju island. The internal organs and ascites of the liver, kidney, spleen, heart, and brain of diseased fish were aseptically extracted using BHIA (Difco, USA) medium supplemented with 1.5% NaCl, Followed by incubation for 28 hours. Among the isolated S. aureus strains, virulent strains were selected for their virulence and growth, and selected strains were selected as HFTC 0045 and HFTC 0045. HFTC 0049, J101. A photograph of a purely isolated colony according to the culture medium of the strain is shown in [Fig. 1] and [Fig. 2] below.

In the case of S. parauberis , it was confirmed that the mutation resistance of the serotype was not recognized during the development. Two serotype 1a strains (HFTC 0045 and HFTC 0049), serotype 1b / c Three S. parauberis isolates including one (J101) isolate were newly selected as vaccine strains.

In order to identify the selected strain, S. parauberis, Kinya, Mata ( 2015), Mata et al (2004), such as reported by specific primers (Specific primer) the production (Bioneer) and polymerase chain reaction (PCR) for the ( PCR) was performed to identify the streptococci. [Figure 3] [Figure 4]

PCR was performed using Accupower PCR premix (Bioneer, Korea). The PCR conditions were predenaturation (94 ℃ for 5 min), denaturation (95 ℃ for 30 sec), annealing (55 ℃ for 30 sec), extension (72 ℃, 30 seconds) was repeated 30 cycles long and final extension (72 ℃, 5 minutes) was performed. The polymerase chain reaction (PCR) product was electrophoresed on a 1.0% agarose gel (agarose gel) with 0.5 μg / ml EtBr (acridium bromide) To confirm the final product of 718 bp. The amplified polymerase chain reaction (PCR) products were analyzed for nucleotide sequences using AccuPrep PCR purification kit (Bioneer) and AccuPrep PCR plasmid extension kit (Bioneer).

The 23S rRNA sequence of the above strain and the genetic information of the Streptococcus bacteria registered in GenBank were subjected to multiple alignment using the Squman program and the homology between the respective species was compared. The nucleotide sequence of the 23S rRNA gene was analyzed and found to be 99% or more homologous with the Streptococcus parauberis KCTC11537 strain registered in GenBank, HFTC 0045, HFTC 0049 and J101 were finally identified as Streptococcus parauberi. After the PCR, the 718 bp common band was electrophoresed with Gel-Doc (Bio-Rad), HFTC 0045 and HFTC 0049 were 213 bp with serotype 1a and J101 was serotype 1b / The final product of 303 bp was identified as c, and the result was as shown in [FIG. 5] and [FIG. 6].

Example 2 Characterization of Streptococcus parauberis HFTC 0045, HFTC 0049 and J101

 <2-1> Microbiological biochemical test

Streptococcus parauberis HFTC 0045, HFTC 0049, J101 identified in Example 1 The microbial biochemistry was attempted to analyze the characteristics of the microorganisms. [Table 2]

As a result of microbiological biochemical tests, the microbiological biochemical properties of S. parauberis showed that the negative reaction was negative for the indole production, Voges-Proskauer (VP) test, Oxidase, catalase, Hemolytic activity was observed in 5% BAP supplemented medium (BAP), and lactose and mannitol tests were different.

<2-2> Microbiological enzyme activity test

 The enzyme activity and the sugar fermentation of the vaccine strain identified in Example 1, the known Streptococcus parauberius strain (KCTC3651) and the flounder vaccine of the Company were measured.

Using enzyme ZYM kit (BioMerieux, France), the activities of 18 enzymes including alkaline phophatase were tested. The results were positive for Acid phospatase and Alkaline phosphatase, and negative for -mannosidase and -fucosidase. . When compared with the reference strain KCTC3651, there was a difference in the enzyme activities such as -galactosidase, -glucosidase and N-acetyl-glucosaminidase.

<2-3> Pathogenic experiment

The HFTC 0045, HFTC 0049, and J101 strains were inoculated into the peritoneal cavity at a dose of about 1 × ^{10 8} CFU / ml in the active abdomen, and water temperature of 18 ° C And observed clinical signs and mortality for 14 days. Clinical symptoms include head haemorrhage, abdominal distension, mucus hyperplasia, and exophthalmos. Autopsy findings of the lungs show multiple ascites, leprosy, and hepatic bleeding. Histopathologic findings of the kidneys showed leukocyte infiltration, liver atrophy, and leukocytosis of the spleen.

Each of the strains exhibiting high mortality was adjusted to 1.0 × 10 ⁸ CFU / ml (1 × 10 ⁷ CFU / 0.1 ml) and diluted to 10-fold to obtain a minimum concentration of 1.0-1.5 × 10 ² CFU / ml × 10 ¹ CFU / 0.1 ml). LD60 was confirmed with a diluted concentration of the strain and 0.1 ml of the prepared bacterial solution was intraperitoneally injected into 10 test fishes per test group. In the control group, the same amount of physiological saline was intraperitoneally injected and the cumulative mortality rate Respectively. Detailed logbooks are shown in Table 4 below.

As a result, the severity of pathogenicity of the three strains of S. parauberis in each vaccine strain was 10 ^2.0 cfu / ㎖. The anatomical symptoms and external findings of the dead individuals after the attack were as shown in Figs. 7, 8 and 9.

Example 3: Preparation of strain for vaccine preparation

The following two strains were prepared for vaccine production. In the same manner as in Example 1,

Alpha-hemolytic streptococcus parauberis HFTC 0045,

Alpha-hemolytic streptococcus parauberis HFTC 0049,

Alpha-hemolytic streptococcus parauberis J101

Example 4: Pathogenicity of strain for vaccine preparation

The LD value of the vaccine strain of Example 3 was determined by a method well known in the art (Hall, JA and Golding, LA: Report of the MFE 80205. NIWA report for standard methods for whole effluent toxicity testing the ministry for environment, Wellington, New Zealand, 1988).

Example 5: Preparation and inoculation of mixed inactivated vaccine

<5-1> Preparation of vaccine

Streptococcus parauberis inactivated mycobacterial antigen (HFTC 0045, HFTC 0049, J101), which has been confirmed as a final isolate, was used as an outdoor isolate from the intact leg body. Bacterial strains identified by isolation and identification were plated on Blood agar or THBA supplemented with 1.5% NaCl (agar added to Todd Hewitt Broth) and cultured overnight at 25 ° C for 18 24 hours. Single colonies were selected The cells were transplanted into THB (Todd-Hewitt Broth) supplemented with 1.5% NaCl and incubated at 25 ° C for 15-18 hours. The cells were lyophilized and stored in cold dark place at -20 ° C or lower. After lyophilization and dissolution of the strain in a cold dark place at -20 ° C or lower in sterile saline, the cells were plated on THBA supplemented with blood agar or 1.5% NaCl, incubated at 25 ° C for 24-48 hours, Were selected and transplanted into THB supplemented with 1.5% NaCl and cultured at 25 ° C for 15-18 hours with shaking. The primary culture medium of THB supplemented with 1/100% of 1.5% NaCl in the present culture medium is inoculated with 1% of the primary culture medium and shake cultured for 10 to 15 hours.

The THB medium supplemented with 1.5% NaCl was completely dissolved in a fermenter and sterilized by high-pressure steam at 121 ° C for 20 minutes. When sterilization was completed, the mixture was cooled with cooling water and inoculated with the final prepared seed culture at 25 ° C Measure the OD value at 600 nm at appropriate intervals using a UV-spectrophotometer (SHIMADZU Co.) while culturing at 25 ° C for 15 - 18 hours and cultivate to the required concentration. When the OD ₆₀₀ of the final culture reaches 1.1 or higher (about 1x10 ⁹ cfu / ml), a sample is taken to investigate whether or not the bacteria are mixed. The culture medium is inactivated for 18-24 hours by adding 0.3% formalin. When inactivation is complete, collect only the cells using a Tomoe-sharples centrifuge and resuspend them in sterile phosphate buffered saline (PBS).

 After centrifuging and resuspension, formalin was added to the bulk to a concentration of 0.5%, and the mixture was inactivated by shaking for 72 hours at 37 ° C in a thermostatic chamber, stored at 5 ° C, (Bulk of each inactivated cell should be cultured in a medium corresponding to each strain for 3 days at 25 ° C, so that no bacterial growth occurs.)

Streptococcus parauberis HFTC 0045, HFTC 0049, and J101 antigens inactivated are mixed at a ratio of 1: 1: 1 to prepare a mixed inactivated vaccine for preventing Streptococcus infection.

<5-2> Inoculation of vaccine

Strength legs were used as a test fish. For the vaccination of the intact legs, each test vaccine was mixed with the same amount by intraperitoneal injection, and intraperitoneally injected 0.1 ml per fish body. In the control group, the same amount of sterilized physiological saline was intraperitoneally injected.

Example 6: Immunogenicity test of inactivated vaccine

<6-1>: Investigation of Defense

In order to investigate the effect of the test vaccine on the defense strength, S. parauberis HFTC 0045 and HFTC 0049, which were the same strains after immunization for 3 weeks, were intraperitoneally injected with 0.1 ml of LD ₆₀ value determined after pathogenic test. Mortality was investigated.

After 4 weeks from the attack, check the survival of the experimental strength legs and calculate the relative survival rate according to the following formula. Relative survival rates were calculated as shown in Table 6 below.

After vaccination for antigenic determinant test, efficacy test through attack inoculation confirmed the RPS value of over 90%, and the vaccine antigen amount was determined based on high relative survival rate.

Example 7: Safety investigation and vaccination control compared to mixed inactivated vaccine administration

<7-1> Safety investigation of vaccine treatment according to the present invention

Histopathological examination of the mixed vaccine peritoneal injection group and the control group of Example 6 was performed. The liver, kidney and spleen tissues of the test specimens were fixed on 10% neutral formalin on day 1, 1 week, and 4 weeks after vaccination. H & E staining was performed according to the conventional method, and the specimens were examined. As a result, normal tissues were observed in all the organs of the vaccinated plants, and it was confirmed that the vaccine was not toxic through [Fig. 13, 14, 15]. The results of histological examination of the dead organisms of the vaccinated group not vaccinated were as shown in [Fig. 16, 17, 18].

Table 1: Origin and main information of the vaccine strain in the strain.
[Table 2] = Information on microbiological biochemical test results of the strain.
[Table 3] = Result of enzyme activity test (API ZYM) of the strain.
[Table 4] = 2-week observation log of the strain inoculated with the above strain. After 10-minute dilution, 0.1 ml of each strain was inoculated into each of ten intact legs and observed for 14 days. The maximum dilution with a cumulative mortality rate of 60% And the LD60 value of the final vaccine strain was confirmed.
Table 5 shows the results of confirming the LD60 value of the final strains.
[Table 6] = Relative survival rate.

Korea Biotechnology Research Institute KCTC18522P 20161130 Korea Biotechnology Research Institute KCTC18523P 20161130 Korea Biotechnology Research Institute KCTC18525P 20161130

Claims (11)

The new alpha-hemolytic Streptococcus parabeuris HFTC 0045 strain (microorganism deposit number KCTC18523P) and the novel alpha-hemolytic Streptococcus parauberius J101 strain (microorganism deposit number: KCTC18522P) 0.0 &gt; KCTC18525P). &Lt; / RTI &gt; The method according to claim 1, wherein the new α-hemolytic Streptococcus parauberius HFTC 0045 strain (microorganism deposit number KCTC18522P), the novel α-hemolytic streptococcus parauberis HFTC 0049 strain (microorganism deposit number KCTC18523P) Wherein the Coccus parauberius strain J101 (microorganism deposit number KCTC18525P) is mixed in a weight ratio of 1: 1: 1. The new alpha-hemolytic Streptococcus parabeuris HFTC 0045 strain (microorganism deposit number KCTC18523P) and the novel alpha-hemolytic Streptococcus parauberius J101 strain (microorganism deposit number: KCTC18522P) Microorganism deposit number &lt; RTI ID = 0.0 &gt; KCTC18525P). &Lt; / RTI &gt; 4. The method according to claim 3, wherein the new alpha-hemolytic Streptococcus parauberius HFTC 0045 strain (microorganism deposit number KCTC18522P), the novel alpha-hemolytic streptococcus parauberis HFTC 0049 strain (microorganism deposit number KCTC18523P) The method for producing a mixed inactivated vaccine for preventing streptococcal disease according to any one of claims 1 to 3, wherein Coccus parauberius strain J101 (microorganism deposit number KCTC18525P) is mixed at a weight ratio of 1: 1: 1. The mixed inactivated vaccine according to claim 1, wherein the strain of HFTC 0045 is inactivated by being separated from an intact leg infected with streptococci. 4. The method of claim 3, wherein the HFTC 0045 strain is inactivated by inactivation from an intact leg infected with streptococci. The mixed inactivation vaccine according to claim 1, wherein the strain of HFTC 0049 is inactivated separately from an intact leg infected with streptococci. 4. The method according to claim 3, wherein the strain HFTC 0049 is inactivated by being separated from an intact leg infected with streptococci. 2. The mixed inactivated vaccine according to claim 1, wherein the strain J101 is inactivated separately from an intact leg infected with streptococci. 4. The method according to claim 3, wherein the strain J101 is inactivated separately from an intact leg infected with streptococci. A method for immunizing a fish, wherein the vaccine of claim 1 or 2 is injected into the abdominal cavity of the fish.

Images